JBT101-DM-002
Official Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Study Details
The purpose of this study is to investigate the efficacy and safety of lenabasum in participants with dermatomyositis.
Principal Investigator
Dr. Heather Jones
IRB Number
201812065
Eligibility
Inclusion:
1. Participants must be 18 years of age or older.
2. Participants must have a history of dermatomyositis with current active disease.
3. Participants must be willing to not use any cannabinoids, including recreational marijuana, medical marijuana and other prescription cannabinoids from screening through end of study.
4. Participants must not have unstable dermatomyositis or end-stage organ involvement and must not have history of cancer (except for treated basal or squamous cell carcinoma of the skin or cervical carcinoma in situ) within 3 years of enrollment.
Volunteer Information
For more information about this study, contact Volunteer for Health at:
- 314.362.1000
- rprstaff@wustl.edu